{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:09Z","timestamp":1792827849591,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Chinese National Key R&D Project","award":["2016YFC1301303"],"award-info":[{"award-number":["2016YFC1301303"]}]},{"name":"Chinese National Key R&D Project","award":["2016YFC1301300"],"award-info":[{"award-number":["2016YFC1301300"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["2020YFC2004701"],"award-info":[{"award-number":["2020YFC2004701"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Vicagrel, a novel antiplatelet prodrug to overcome the residual high platelet reactivity of clopidogrel induced by inactive metabolism and cytochrome P450 (CYP) 2C19 polymorphisms, provides favourable antiplatelet inhibition in healthy volunteers. However, its antiplatelet effect and safety in patients with coronary artery disease (CAD) are unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This was a multicentre, randomized, double-blind, triple-dummy, dose-exploring phase II trial comparing the antiplatelet activity and safety of vicagrel at different doses vs. those of clopidogrel in patients with CAD undergoing percutaneous coronary intervention (PCI). The primary endpoint was inhibition of adenosine diphosphate (ADP)-induced platelet aggregation (%IPA) after loading and maintenance doses (LD\/MD) at 28 days. Safety endpoints included adverse events (AEs) and Bleeding Academic Research Consortium-defined any bleeding. Pharmacokinetic (PK) profiles and the influence of CYP2C19 polymorphisms were explored in subgroup analysis. Two hundred and seventy-nine patients diagnosed with stable CAD (51.97%), unstable angina (40.86%), and myocardial infarction (7.17%) were randomized to receive vicagrel 20\/5\u00a0mg (LD\/MD), 24\/6\u00a0mg, or 30\/7.5\u00a0mg or clopidogrel 300\/75\u00a0mg in combination with aspirin. %IPAs on Day 28 were 30.19%, 35.02%, 45.61%, and 32.55% for vicagrel 20\/5, 24\/6, and 30\/7.5\u00a0mg and clopidogrel, respectively, and were comparable across all groups (P\u00a0=\u00a00.0694). The plasma concentration of the vicagrel active metabolite M15-2 had a similar area under curve and Tmax to those of clopidogrel. There were no significant differences in AEs (4.35%, 0%, 1.45%, and 5.56% for vicagrel 20\/5, 24\/6, and 30\/7.5\u00a0mg and clopidogrel, P\u00a0=\u00a00.6667) or any bleeding (13.04%, 14.06%, 11.59%, and 11.11% for vicagrel 20\/5, 24\/6, and 30\/7.5\u00a0mg and clopidogrel, respectively, P\u00a0=\u00a00.95) across four groups. %IPAs and PK profiles of vicagrel did not vary significantly among different CYP2C19 metabolizers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vicagrel had comparable antiplatelet effect and safety to clopidogrel in patients with CAD undergoing PCI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac026","type":"journal-article","created":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T19:06:37Z","timestamp":1650222397000},"page":"806-814","source":"Crossref","is-referenced-by-count":19,"title":["Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention"],"prefix":"10.1093","volume":"8","author":[{"given":"Xin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"},{"name":"Department of Cardiology, the Second Hospital of Jilin University , Changchun, Jilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Heart Center, First Hospital of Tsinghua University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongda Hospital Southeast University , Nanjing, Jiangsu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the Second Hospital of Jilin University , Changchun, Jilin , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China\u2013Japan Friendship Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Hospital of Hebei Medical University , Shijiazhuang, Hebei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jiangxi Provincial People's Hospital , Nanchang, Jiangxi , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines and Center of Drug Discovery, College of Pharmacy, China Pharmaceutical University , Nanjing, Jiangsu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"R&D Department, Jiangsu Vcare PharmaTech Co. , Ltd, Nanjing, Jiangsu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Lai","sequence":"additional","affiliation":[{"name":"R&D Department, Jiangsu Vcare PharmaTech Co. , Ltd, Nanjing, Jiangsu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Gong","sequence":"additional","affiliation":[{"name":"R&D Department, Jiangsu Vcare PharmaTech Co. , Ltd, Nanjing, Jiangsu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguo","family":"Li","sequence":"additional","affiliation":[{"name":"R&D Department, Guangzhou JOYO Pharma Ltd , Guangzhou, Guangdong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhao","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-6737","authenticated-orcid":false,"given":"Yaling","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Northern Theater Command , No. 83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"2022120213161300900_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2022120213161300900_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2022120213161300900_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2022120213161300900_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022120213161300900_bib5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2022120213161300900_bib6","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"2022120213161300900_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-020-00864-4","article-title":"Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists","volume":"59","author":"Schilling","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2022120213161300900_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2022120213161300900_bib9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2022120213161300900_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41401-020-00547-7","article-title":"Pharmacokinetics, mass balance, and metabolism of [(14)C]vicagrel, a novel irreversible P2Y12 inhibitor in humans","volume":"42","author":"Zheng","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"2022120213161300900_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2018.10.011","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing","volume":"127","author":"Liu","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2022120213161300900_bib12","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/bcp.14296","article-title":"Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor","volume":"86","author":"Zhang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2022120213161300900_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fphar.2018.00643","article-title":"Evaluation of tolerability, pharmacokinetics and pharmacodynamics of vicagrel, a novel P2Y12 antagonist, in healthy Chinese volunteers","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022120213161300900_bib14","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2022120213161300900_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2022120213161300900_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jpba.2017.11.019","article-title":"Development and validation of a sensitive and rapid UHPLC-MS\/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma","volume":"149","author":"Liu","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"2022120213161300900_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40262-015-0273-3","article-title":"Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen","volume":"54","author":"de Vries Schultink","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2022120213161300900_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2022120213161300900_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of clopidogrel","volume":"54","author":"Jiang","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2022120213161300900_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11095-013-1158-5","article-title":"Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel","volume":"31","author":"Qiu","year":"2014","journal-title":"Pharm Res"},{"key":"2022120213161300900_bib21","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm300038c","article-title":"Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent","volume":"55","author":"Shan","year":"2012","journal-title":"J Med Chem"},{"key":"2022120213161300900_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/jps.23394","article-title":"Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs","volume":"102","author":"Qiu","year":"2013","journal-title":"J Pharm Sci"},{"key":"2022120213161300900_bib23","doi-asserted-by":"crossref","first-page":"591854","DOI":"10.3389\/fphar.2020.591854","article-title":"Predicting the effects of CYP2C19 and carboxylesterases on vicagrel, a novel P2Y12 antagonist, by physiologically based pharmacokinetic\/pharmacodynamic modeling approach","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol"},{"key":"2022120213161300900_bib24","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.biopha.2019.108906","article-title":"Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation","volume":"115","author":"Jia","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2022120213161300900_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac026\/43923729\/pvac026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/8\/806\/47516289\/pvac026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/8\/806\/47516289\/pvac026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:17:09Z","timestamp":1669987029000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/8\/806\/6570569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4,19]]},"published-print":{"date-parts":[[2022,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac026","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,4,19]]}}}